Internal Medicine, Medical Oncology · Boston, MA
NPI
1952538639
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
75 Francis St
Boston, MA, 02115
Phone (617) 732-5500
Groups this clinician bills Medicare through
Medicare paid, 2024
$51K
604 services
Medicare patients, 2024
209
Average age 75
Drug cost, 2024
$3.1M
479 prescriptions
Company payments, 2025
$27K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Marlise R Luskin was code 99214 (office e&m - established), 170 times for 87 patients. In total Marlise R Luskin billed 604 services in 10 codes, and Medicare paid $51K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 170 | 87 | $76.18 | $13K |
| 99232 Hospital E&M - Subsequent | Facility | 131 | 26 | $65.74 | $8,612 |
| 99215 Office E&M - Established | Facility | 110 | 64 | $116.95 | $13K |
| 99213 Office E&M - Established | Facility | 104 | 63 | $52.61 | $5,471 |
| 99205 Office E&M - New | Facility | 41 | 41 | $151.56 | $6,214 |
| 99238 Hospital Discharge Management | Facility | 19 | 18 | $68.25 | $1,297 |
By year: 2022 $60K for 636 services; 2023 $62K for 784 services; 2024 $51K for 604 services.
Medicare prescription drug claims, 2024
In 2024, the drug Marlise R Luskin prescribed most often to Medicare patients was Valacyclovir (Valacyclovir Hcl), with 53 prescriptions and refills. In total Marlise R Luskin wrote 479 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Valacyclovir Valacyclovir Hcl | 53 | 85 | 14 | $2,643 |
| Jakafi Ruxolitinib Phosphate | 34 | 34 | Under 11 | $502K |
| Venclexta Venetoclax | 32 | 32 | 17 | $273K |
| Hydroxyurea Generic | 22 | 44 | Under 11 | $354 |
| Xospata Gilteritinib Fumarate | 21 | 23 | Under 11 | $598K |
| Levofloxacin Generic | 17 | 17 | Under 11 | $253 |
| Amlodipine Besylate Generic | 14 | 16 | Under 11 | $95.26 |
| Acyclovir Generic | 13 | 25 | Under 11 | $205 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 13 | 13 | Under 11 | $40.29 |
| Inqovi Decitabine/Cedazuridine | 11 | 11 | Under 11 | $84K |
Brand drugs: 171 claims; generic drugs: 308 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Marlise R Luskin $27K ($22K in general payments such as food, travel and fees and $4,582 for research) from 7 companies. The largest payer was Abbvie Inc. with $7,997.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.